跳到正文
原文
MedPage Today·· 16 天前精选AI 评分68

FDA顾问委员会未推荐批准SYD-101低剂量阿托品眼药水

FDA Panel Largely Pans Trial Data for Myopia Eye Drops

AI 导读

FDA顾问委员会在审议SYD-101低剂量阿托品眼药水用于减缓儿童近视进展的III期临床数据后,未推荐批准。主要原因是数据缺乏临床意义,且存在数据缺失和统计稳健性问题。

推荐理由

FDA顾问委员会未推荐批准SYD-101低剂量阿托品眼药水,主要因数据不具临床意义。

正文

— Atropine slowed progression but clinical meaningfulness, robustness of data questioned

November 3, 2026 • 5 min read

The regulatory status of a low-dose atropine eye drop formulation for myopia remained unresolved following a day-long FDA advisory committee meeting, but closing comments did not bode well for SYD-101.

The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) did not vote to recommend for or against approval of the eye drops, but panelists' responses to key questions posed by the FDA suggested the evidence from a phase III trial of SYD-101 did not meet standards for approval.

"Basically, the summary is that, although the clinical trial is positive, it's not a robust outcome that would meet the standard presented to us as the reason for approval by the FDA," said DODAC Acting Chair Michael X. Repka, MD, of the Johns Hopkins Wilmer Eye Institute in Baltimore. "The issue of missing data remains sort of difficult for this committee to manage."

Supporting Evidence

Primary support for the approval application came from the SYD-101-001 randomized trial (also known as the STAR trial) comparing two doses of atropine sulfate ophthalmic solution versus vehicle to slow myopia progression in 852 pediatric patients 3 years or older. The primary endpoint was the proportion of patients with myopia progression exceeding 0.75 diopters at 36 months.

The primary analysis showed that 39.5% of patients randomized to the 0.01% solution met the primary endpoint as compared with 49.3% of patients randomized to the control group (P=0.0452). The 0.03% treatment arm did not achieve statistical significance versus the control group.

The difference between the 0.01% arm and vehicle translated into progression slowing of 0.079 diopters per year or a cumulative difference of 0.21 diopters versus control. In a briefing document prepared for the meeting, FDA staff said the difference, though statistically significant, was not clinically meaningful and that the magnitude of benefit decreased over time.

Additionally, primary endpoint data were missing for 26% of patients in the 0.01% treatment arm and 23% of the control group. Sensitivity analyses showed the outcome data were influenced by different assumptions about the statistical impact of missing data.

The staff report also noted that the trial failed to show a significant reduction in axial length, which raised questions about the treatment's potential to alter myopia-related structural changes. Half of the participating centers did not measure axial length, and measurement was not uniform at the centers that did. Additionally, "external evidence from other randomized controlled trials conducted in non-Asian Western populations has generally been unsupportive of the efficacy of 0.01% atropine."

Viewpoints on Data

Summarizing the panel's comments regarding the clinical meaningfulness of the differences observed in the trial, Repka said, "The [committee] basically considered the clinical meaningfulness of the observed efficacy profile uncertain, both because of the magnitude, the question of just a shift or delay in myopia progression by the 6-month or 1-year cycle, and also the lack of corroboration on axial length in those centers that were able to perform it. [The committee] would recommend to manufacturers in the future to consider including axial length as a primary or key outcome measure."

The panel also appeared to agree with FDA staff that the published literature did not provide confirmatory evidence, beyond the SYD-101-001 trial, that would rise to the standards necessary for approval.

"When I look at the other studies, they were not as well performed or designed as the [SYD-101-001] study we're discussing," said panelist Timothy G. Murray, MD, of the University of Miami Bascom Palmer Eye Institute. "The size, stratification, and randomization that was done was a plus. The way that the data was looked at is a plus. The other studies fall far below that standard, and therefore, I wouldn't consider that substantial evidence or a standard for approval."

In a separate report for DODAC, representatives of Sydnexis noted that the SYD-101-001 trial was designed with input from the FDA. They emphasized that the trial met the prespecified primary endpoint and that the levels of statistical significance increased in a multiple-adjusted analysis (P=0.0226). Data for the key secondary endpoint also achieved statistical significance for the 0.01% solution versus vehicle (P=0.0002).

Though acknowledging missing data, Sydnexis stated that "missing efficacy data and discontinuations were not meaningfully imbalanced across groups. All prespecified missing-data sensitivity estimates favored SYD-101 0.01%, with treatment estimates generally consistent with the primary result."

DODAC panelists did not dispute the statistical significance of the primary endpoint but rather questioned the robustness and clinical meaningfulness of the results. Murray said the lack of robustness "calls into question our ability to interpret the data further."

Alex Kaizer, PhD, a biostatistician at the University of Colorado Anschutz in Aurora, noted that confidence intervals for efficacy data approached 0%, making the results susceptible to small changes.

"I think what this means to me, with the discussion around the potential clinical significance and the heterogeneity of the patient population, is that it feels like more data is truly needed to understand, especially in younger ages and fast progressors, what the benefit would be," he said.

Acknowledging that the treatment seems promising and is approved elsewhere in the world, Kaizer added, "These borderline results do make it challenging, because if just a few people change their outcome, it could change the result suddenly to a very different discussion than the one we're having today."

Throughout the meeting, several speakers noted that dozens of studies have demonstrated atropine eye drops' efficacy in myopia and that low-dose formulations are available in many nations, but not the U.S. Clinicians in the U.S. can and do prescribe low-dose atropine eye drops, but the medication is available only through compounding pharmacies.

From the Beginning

The DODAC meeting had its genesis in a complete response letter the FDA sent to Sydnexis in October 2025.

"The FDA acknowledged in the complete response letter that this primary endpoint was met but stated its view that the data do not support the effectiveness of low-dose atropine in children with myopia," company officials stated in a press release. "No deficiencies were noted related to safety or product quality."

In response, Sydnexis submitted a formal dispute resolution request to the FDA, which subsequently scheduled the DODAC meeting to consider the evidence in separate presentations by FDA staff and speakers representing Sydnexis, including several pediatric ophthalmologists.

The next step is up to the FDA, and no timetable for a decision was announced at the conclusion of the DODAC meeting.

来源:MedPage Today · medpagetoday.com